FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number: 3235										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Dayno Jeffrey M.			2. Issuer Name and Ticker or Trading Symbol Harmony Biosciences Holdings, Inc. [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
			HRMY]					2	V Director	r		10% Ow	ner				
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)						Officer below)	(give title		Other (spelow)	pecify		
C/O HARMONY BIOSCIENCES HOLDINGS, INC.			l or	05/26/2023						PRESIDENT, CEO							
630 W GERMANTOWN PIKE, SUITE 215			4. If Amendment, Date of Original Filed (Month/Day/Year) 05/30/2023						6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street)												2	K Form fil	ed by One	Repo	orting Person	n
PLYMO MEETIN	- D	A	19462										Form fil Person		e than	One Report	ting
				R	ule	10b5-	1(c)) Transa	ctio	n Ind	ication						
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			. Transactior ate Month/Day/Y	Execution Date		Date	Transaction Dispo		Dispose	ırities Acquired (A) o ed Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia Owned F	es Form ally (D) o Following (I) (In		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
					Code	v /	Amount	(A) (D)	Or Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execution Date, T General Conversion Or Exercise (Month/Day/Year) If any		Code (ansaction Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expi Date	iration e	Title	Amount or Number of Shares		(Instr. 4)	(-/		
Stock Option	\$35.56 ⁽¹⁾	05/26/2023		A		125,000		(2)	05/2	25/2033	Common Stock	125,000	\$0	125,00	00	D	

Explanation of Responses:

- 1. This Form 4/A is being filed to amend the exercise price of the granted options previously reported as being \$35.99 to \$35.56.
- 2. The stock option vests with respect to 50% of the underlying shares on May 25, 2025, with the remaining shares vesting in twenty-four equal monthly installments beginning on June 25, 2025.

/s/ Christian Ulrich, Attorneyin-Fact

05/31/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.